Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Return on Capital Employed (2023 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Return on Capital Employed for 3 consecutive years, with 0.04% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 213.0% to 0.04% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.04%, a 213.0% increase, with the full-year FY2024 number at 0.33%, up 270.0% from a year prior.
  • Return on Capital Employed was 0.04% for Q3 2025 at 60 Degrees Pharmaceuticals, down from 0.1% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.1% in Q2 2025 to a low of 2.09% in Q3 2024.
  • A 3-year average of 0.77% and a median of 0.68% in 2023 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: tumbled -141bps in 2024, then surged 213bps in 2025.
  • 60 Degrees Pharmaceuticals' Return on Capital Employed stood at 0.92% in 2023, then soared by 63bps to 0.34% in 2024, then surged by 113bps to 0.04% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Return on Capital Employed are 0.04% (Q3 2025), 0.1% (Q2 2025), and 0.55% (Q1 2025).